In the latest session, Alignment Healthcare Inc (NASDAQ: ALHC) closed at $5.40 down -4.26% from its previous closing price of $5.64. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 1436977 shares were traded.
Ratios:
For a deeper understanding of Alignment Healthcare Inc’s stock, let’s take a closer look at its various ratios. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on January 24, 2024, initiated with a Buy rating and assigned the stock a target price of $11.
On November 02, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $7.50 to $7.25.
Raymond James Upgraded its Outperform to Strong Buy on October 16, 2023, whereas the target price for the stock was revised from $9 to $10.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 14 when MARGOLIS JEFFREY H sold 1,200 shares for $8.46 per share. The transaction valued at 10,152 led to the insider holds 417,133 shares of the business.
MARGOLIS JEFFREY H sold 1,200 shares of ALHC for $9,600 on Dec 06. The Director now owns 418,333 shares after completing the transaction at $8.00 per share. On Nov 10, another insider, KONOWIECKI JOSEPH S, who serves as the Chairman of the Board of the company, sold 4,898 shares for $5.90 each. As a result, the insider received 28,898 and left with 1,188,221 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALHC now has a Market Capitalization of 1.06B and an Enterprise Value of 916.71M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.56 while its Price-to-Book (P/B) ratio in mrq is 6.50. Its current Enterprise Value per Revenue stands at 0.50 whereas that against EBITDA is -8.71.
Stock Price History:
Over the past 52 weeks, ALHC has reached a high of $9.20, while it has fallen to a 52-week low of $4.88. The 50-Day Moving Average of the stock is 7.27, while the 200-Day Moving Average is calculated to be 6.70.
Shares Statistics:
For the past three months, ALHC has traded an average of 735.29K shares per day and 1.39M over the past ten days. A total of 188.95M shares are outstanding, with a floating share count of 94.88M. Insiders hold about 49.79% of the company’s shares, while institutions hold 43.06% stake in the company. Shares short for ALHC as of Feb 15, 2024 were 4.1M with a Short Ratio of 5.58, compared to 3.65M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.17% and a Short% of Float of 3.43%.
Earnings Estimates
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of -$0.18 and a low estimate of -$0.25, while EPS last year was -$0.2. The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.06 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.29 and -$0.66 for the fiscal current year, implying an average EPS of -$0.56. EPS for the following year is -$0.43, with 9 analysts recommending between -$0.19 and -$0.57.
Revenue Estimates
A total of 9 analysts believe the company’s revenue will be $582.06M this quarter.It ranges from a high estimate of $598.56M to a low estimate of $526.71M. As of the current estimate, Alignment Healthcare Inc’s year-ago sales were $439.15M, an estimated increase of 32.50% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $597.47M, an increase of 36.10% over than the figure of $32.50% in the same quarter last year. There is a high estimate of $620.26M for the next quarter, whereas the lowest estimate is $558.3M.
A total of 10 analysts have provided revenue estimates for ALHC’s current fiscal year. The highest revenue estimate was $2.53B, while the lowest revenue estimate was $2.15B, resulting in an average revenue estimate of $2.39B. In the same quarter a year ago, actual revenue was $1.82B, up 31.10% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $2.88B in the next fiscal year. The high estimate is $3.04B and the low estimate is $2.75B. The average revenue growth estimate for next year is up 20.60% from the average revenue estimate for this year.
